Drugs / loberamisal
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT06429384 | Jun → Nov 2023 | ischemic stroke | Beijing Tiantan Hospital | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT06517173 | Jul 2024 → Apr 2025 | ischemic stroke | Beijing Tiantan Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | loberamisal | “Loberamisal, a novel agent that dissociates the post-synaptic density protein 95/neuronal nitric oxide synthase complex and potentiates the α2-containing γ-aminobutyric acid...” PMID 41344725 ↗ Dec 20251“Loberamisal is a small-molecule agent that inhibits the nNOS-postsynaptic density protein 95 coupling and enhances α2-containing γ-aminobutyric acid type A receptor, which has...” PMID 41218852 ↗ Nov 2025 |
| Action | Inhibit | “inhibits the nNOS-postsynaptic density protein 95 coupling” PMID 41218852 ↗ Nov 2025 |
| Modality | Small molecule | “Loberamisal is a small-molecule agent” PMID 41218852 ↗ Nov 2025 |
| Route | Intravenous | “intravenous loberamisal” PMID 41344725 ↗ Dec 2025 |